Pinnacle Associates Ltd. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,855 shares of the medical instruments supplier’s stock after selling 453 shares during the period. Pinnacle Associates Ltd.’s holdings in Becton, Dickinson and were worth $5,110,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Alyeska Investment Group L.P. raised its stake in Becton, Dickinson and by 12.9% in the fourth quarter. Alyeska Investment Group L.P. now owns 763,909 shares of the medical instruments supplier’s stock worth $126,465,000 after buying an additional 87,503 shares in the last quarter. Sciencast Management LP purchased a new stake in Becton, Dickinson and during the fourth quarter worth $590,000. GLG LLC raised its stake in Becton, Dickinson and by 6.8% in the fourth quarter. GLG LLC now owns 11,921 shares of the medical instruments supplier’s stock worth $1,974,000 after buying an additional 758 shares in the last quarter. Ancora Advisors LLC purchased a new stake in Becton, Dickinson and during the fourth quarter worth $1,196,000. Finally, Ellington Management Group LLC bought a new stake in shares of Becton, Dickinson and during the fourth quarter worth approximately $381,000. 75.61% of the stock is owned by institutional investors.

Becton, Dickinson and Company (NYSE BDX) traded down 1.01% during trading on Thursday, hitting $198.90. 2,570,424 shares of the stock traded hands. The stock has a market cap of $45.22 billion, a P/E ratio of 33.04 and a beta of 1.05. The stock has a 50 day moving average price of $197.67 and a 200-day moving average price of $186.53. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 25.37% and a net margin of 10.67%. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same quarter in the previous year, the company posted $2.35 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. On average, analysts anticipate that Becton, Dickinson and Company will post $9.45 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. Becton, Dickinson and’s dividend payout ratio is 48.26%.

ILLEGAL ACTIVITY NOTICE: “Pinnacle Associates Ltd. Has $5.11 Million Stake in Becton, Dickinson and Company (BDX)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/03/pinnacle-associates-ltd-decreases-position-in-becton-dickinson-and-company-bdx-updated-updated-updated.html.

A number of analysts have recently commented on BDX shares. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 price target for the company in a research note on Tuesday, April 11th. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price target for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Bank of America Corporation restated a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Cowen and Company restated an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and has a consensus rating of “Buy” and an average target price of $194.69.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at $13,171,289.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.